Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SRTA
SRTA logo

SRTA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Strata Critical Medical Inc (SRTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.160
1 Day change
-1.53%
52 Week Range
6.500
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SRTA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below the prior close and technical momentum is not strong enough to justify an immediate purchase. There is no AI Stock Picker or SwingMax buy signal, news is absent, insider and hedge fund activity are neutral, and the short-term pattern suggests downside bias. The only clearly supportive factor is a bullish analyst rating and a higher price target, but that alone is not enough to make this a direct buy today.

Technical Analysis

The technical picture is mixed to slightly bearish. MACD histogram is negative at -0.0627 and still contracting, which points to weakening momentum. RSI_6 is 46.862, which is neutral and does not confirm oversold conditions. Moving averages are converging, suggesting a lack of strong trend direction. Price closed at 5.31, below the previous close of 5.41 and below the pivot level of 5.507, which reinforces near-term weakness. Support sits at 5.163, then 4.951, while resistance is 5.851 and 6.063. The stock trend data also indicates a high probability of further weakness over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options positioning is bullish in sentiment terms because the open interest put-call ratio of 0.28 is very low, showing far more calls than puts. However, the market is pricing extreme volatility, with 30-day implied volatility at 317.2% and IV percentile at 100, which means options are expensive and the market expects large swings. Daily option volume is light, so the bullish options bias is more sentiment-based than confirmation of active demand.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
4

Positive Catalysts

  • ["Ladenburg raised its price target to $11.50 from $11.25 and maintained a Buy rating.", "Options open interest is heavily call-skewed, with a low put-call ratio of 0.28.", "No recent negative news was reported in the last week."]

Neutral/Negative Catalysts

  • ["No recent news catalysts in the past week to drive momentum.", "MACD is negative and weakening, pointing to poor short-term trend strength.", "RSI is neutral, offering no strong entry confirmation.", "Price is trading below the pivot level, indicating near-term weakness.", "Pattern-based trend data suggests downside over the next day, week, and month.", "Hedge funds and insiders are both neutral with no meaningful accumulation signal.", "No AI Stock Picker or SwingMax signal is present today."]

Financial Performance

No reliable latest-quarter financial snapshot was provided because the financial data feed returned an error. As a result, there is no usable quarterly revenue or earnings trend to confirm fundamental acceleration. The latest quarter season could not be identified from the available data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wall Street sentiment is constructive but not decisive. The latest analyst action was on 2026-05-07, when Ladenburg's Jon Hickman raised the price target to $11.50 from $11.25 and kept a Buy rating. That supports a bullish long-term view, but there is no broader evidence of widespread analyst upgrades or improving target trends. The pros view is that the stock has meaningful upside versus the current price; the cons view is that price action, momentum, and lack of fresh catalysts do not yet confirm that upside.

Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
Wall Street analysts forecast SRTA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.240
sliders
Low
8
Averages
9.63
High
11.25
Current: 5.240
sliders
Low
8
Averages
9.63
High
11.25
Ladenburg
Jon Hickman
Buy
maintain
AI Analysis
2026-05-07
Reason
Ladenburg
Jon Hickman
Price Target
AI Analysis
2026-05-07
maintain
Buy
Reason
Ladenburg analyst Jon Hickman raised the firm's price target on Strata Critical Medical to $11.50 from $11.25 and keeps a Buy rating on the shares.
Craig-Hallum
Bill Bonello
initiated
$8
2026-03-25
Reason
Craig-Hallum
Bill Bonello
Price Target
$8
2026-03-25
initiated
Reason
As previously reported, Craig-Hallum analyst Bill Bonello initiated coverage of Strata Critical Medical with a Buy rating and $8 price target. Over the past year, the company has executed a major strategic transformation and, as a result, it is not well-covered and its growth prospects are underappreciated, the firm argued. Craig-Hallum expects multiple expansion as the market starts to understand the business, becomes more confident in the growth prospects, and comes to believe that estimates are conservative.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SRTA
Unlock Now

People Also Watch